BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants.

Core Insights - BioPorto is actively participating in the Association for Diagnostics & Laboratory Medicine meeting, focusing on NGAL and Acute Kidney Injury (AKI) [1][4] - The conference highlights the importance of early detection of AKI, particularly in pediatric populations, using NGAL as a promising biomarker [2][4] - BioPorto's ProNephro AKI™ (NGAL) is FDA cleared for risk stratification of ICU patients aged 3 months to 21 years for moderate to severe AKI [4][11] Industry Focus - AKI remains a critical topic in laboratory medicine, especially with changes in eGFR calculations and the transition from AKI to Chronic Kidney Disease (CKD) [2] - The conference includes special sessions on next-generation biomarkers for early prediction and diagnosis of AKI, emphasizing the need for innovative diagnostic tools [3][2] - Ongoing interest in AKI is expected to continue into 2025 and 2026, driven by the KDIGO project to update AKI guidelines [6] Company Initiatives - BioPorto is promoting its NGAL tests to lab directors and clinical managers at the conference, aiming to enhance awareness and adoption of its products [4][7] - The company is engaging with worldwide partners to review collaborations and the business impact of its FDA cleared products [5] - BioPorto's focus on actionable biomarkers aims to improve clinical outcomes and patient management in AKI [10][11]